Last mentioned: 5d ago
Collaboration Announced at BIO 2026
Insilico Medicine and SK Biopharmaceuticals announced a research and development collaboration, value up to $2.5 billion, to discover AI‑enabled drug candidates for neuroimmune disorders of the CNS.
Insilico Medicine's Pharma.AI generative AI platform landed a record $2.5B collaboration with SK Biopharmaceuticals to design and optimize therapeutics for neuroimmune disorders. The deal, announced at BIO 2026, represents the largest validation of an end‑to‑end AI drug discovery engine in the CNS space, proving that generative modeling can transcend oncology and infuse new life into neurology pipelines.
This page surfaces every story mentioning BIO International Convention 2026 across our ai coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running ai beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where BIO International Convention 2026 was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |